

DTOS Rec'd PCT/PTO 01 SEP 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: Based on PCT/JP03/02564  
Filed: Intl. Filing 05 MARCH 2003  
1<sup>st</sup> Inventor: Atsushi NAKANISHI  
For: Novel Protein and DNA Thereof  
Atty. Dkt. No. 3030 USOP

Art Unit: tba

Examiner: tba

Allowed:

Batch:

Paper No.:

10/506308

#3

**Information Disclosure Statement**

MAIL STOP PCT  
P.O. Box 1450  
Commissioner for Patents  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached Form PTO/SB/08A. A legible copy of each listed reference is herewith being provided to the Examiner.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3372.

Respectfully submitted,

Dated:

(847) 383-3372  
(847) 383-3391



Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43,032  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

**Complete if Known**

10/506308

Application Number	Based on FCHJP03/02864
--------------------	------------------------

Filing Date	Intl. Filing 05 MARCH 2003
-------------	----------------------------

First Named Inventor	Atsushi NAKANISHI
----------------------	-------------------

Art Unit	tba
----------	-----

Examiner Name	tba
---------------	-----

Attorney Docket Number	3030 US0P
------------------------	-----------

Sheet	1	of	2
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> *Number <sup>4</sup> *Kind Code <sup>5</sup> (if known)				
	A1	WO 01/54477 A2-Cover Page	08/02/2001	Hyseq, Inc.		<input checked="" type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

0109 Rec'd PCT/PTO 0 1 SEP 2004

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	Based on PCT/JPO30256 <b>10/506308</b>
Filing Date	Intl. Filing 05 MARCH 2003
First Named Inventor	Atsushi NAKANISHI
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3030 US0P

Sheet 2 of 2

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A2	Y. OKAZAKI, et al., "Analysis of the Mouse Transcriptome Based on Functional Annotation of 60,770 Full-Length cDNAs", Nature, (2002), pp. 563-573, Vol. 420, No. 6915	✓
	A3	S. KONDO, et al., "Computational Analysis of Full-Length Mouse cDNAs Compared with Human Genome Sequences", Mammalian Genome, (2001), pp. 673-677, Vol. 12, No. 9.	✓
	A4	H. KONNO, et al., "Computer-Based Methods for the Mouse Full-Length cDNA Encyclopedia: Real-Time Sequence Clustering for Construction of a Nonredundant cDNA Library", Genome Research, (2001), pp. 281-289, Vol. 11, No. 2.	✓
	A5	H. KUSUHARA, et al., "Role of Transporters in the Tissue-Selective Distribution and Elimination of Drugs: Transporters in the Liver, Small Intestine, Brain and Kidney", Journal of Controlled Release, (2002), pp. 43-54, Vol. 78, Nos. 1-3.	✓
	A6	I. TAMAI, et al., "Molecular Identification and Characterization of Novel Members of the Human Organic Anion Transporter (OATP) Family", Biochemical and Biophysical Research Communications, (2000), pp. 251-260, Vol. 273.	✓
	A7	B. HAGENBUCH, et al., "The Superfamily of Organic Anion Transporting Polypeptides", Biochim. Biophys. Acta (2003), pp. 1-18, Vol. 1609, No. 1. GenBank#NM030958	✓
	A8	R.L. STRAUSBERG, et al., "Generation and Initial Analysis of More than 15,000 Full-Length Human and Mouse CDNA Sequences", Proc. Natl. Acad. Sci. USA (2002), pp. 16899-16903, Vol. 99, No. 26., GenBank#NP076397	✓
	A9	K. FUJIWARA, et al., "Identification of Thyroid Hormone Transporters in Humans: Different Molecules are Involved in a Tissue-Specific Manner", (2001), pp. 2005-2012, Vol. 142, No. 5	✓

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.